Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2002 1
2004 1
2005 2
2006 3
2007 2
2008 2
2011 2
2012 3
2013 5
2014 9
2015 10
2016 9
2017 11
2018 17
2019 22
2020 11
2021 25
2022 20
2023 16
2024 24
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Wiviott SD, et al. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
Secondary efficacy outcomes were a renal composite (40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m(2) of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. ...
Secondary efficacy outcomes were a renal composite (40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 …
The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management.
Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, Aghamohammadi A. Yazdani R, et al. Clin Immunol. 2019 Jan;198:19-30. doi: 10.1016/j.clim.2018.11.007. Epub 2018 Nov 13. Clin Immunol. 2019. PMID: 30439505 Review.
Hyper Immunoglobulin M syndrome (HIGM) is a rare primary immunodeficiency disorder characterized by low or absent levels of serum IgG, IgA, IgE and normal or increased levels of serum IgM. ...
Hyper Immunoglobulin M syndrome (HIGM) is a rare primary immunodeficiency disorder characterized by low or absent levels of serum IgG …
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.
Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, Kodali SK, Kapadia SR, Cohen DJ, Pocock SJ, Lu M, White R, Szerlip M, Ternacle J, Malaisrie SC, Herrmann HC, Szeto WY, Russo MJ, Babaliaros V, Smith CR, Blanke P, Webb JG, Makkar R; PARTNER 3 Investigators. Mack MJ, et al. N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJMoa2307447. Epub 2023 Oct 24. N Engl J Med. 2023. PMID: 37874020 Clinical Trial.
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis.
Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, Lindman BR, Babaliaros V, Fearon WF, Daniels DV, Chhatriwalla AK, Kavinsky C, Gada H, Shah P, Szerlip M, Dahle T, Goel K, O'Neill W, Sheth T, Davidson CJ, Makkar RR, Prince H, Zhao Y, Hahn RT, Leipsic J, Redfors B, Pocock SJ, Mack M, Leon MB; EARLY TAVR Trial Investigators. Généreux P, et al. N Engl J Med. 2025 Jan 16;392(3):217-227. doi: 10.1056/NEJMoa2405880. Epub 2024 Oct 28. N Engl J Med. 2025. PMID: 39466903 Clinical Trial.
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Mack MJ, et al. N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16. N Engl J Med. 2019. PMID: 30883058 Clinical Trial.
Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Akiyama H, et al. Leukemia. 2024 Apr;38(4):729-740. doi: 10.1038/s41375-023-02117-2. Epub 2023 Dec 26. Leukemia. 2024. PMID: 38148395 Free PMC article.
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators. Nissen SE, et al. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13. N Engl J Med. 2016. PMID: 27959716 Free article. Clinical Trial.
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
182 results